中国儿童淋巴瘤协作组成熟B细胞淋巴瘤2017方案治疗儿童伯基特淋巴瘤的中期疗效
该研究回顾性分析436例≤18岁伯基特淋巴瘤患儿,均按CNCL-B-NHL-2017方案分层治疗。全组2年无事件生存率为(90.9±1.4)%,利妥昔单抗联合化疗组高于单纯化疗组,Ⅳ期、LDH>正常值4倍及中期评估有瘤灶为预后不良危险因素。
要点
- CNCL-B-NHL-2017方案治疗儿童伯基特淋巴瘤全组2年EFS达(90.9±1.4)%。
- 利妥昔单抗联合化疗组2年EFS(92.9±1.4)%高于单纯化疗组(79.3±5.1)%。
- Ⅳ期、LDH>正常值4倍、中期评估有瘤灶为预后不良危险因素。
核心结论
- CNCL-B-NHL-2017方案对儿童伯基特淋巴瘤疗效显著,联合利妥昔单抗可进一步提高疗效。
研究设计与样本
- 回顾性收集中国儿童淋巴瘤协作组2017年5月至2021年4月收治的436例年龄≤18岁伯基特淋巴瘤患儿临床资料,均按CNCL-B-NHL-2017方案分层治疗。
主要发现
- 436例患儿发病年龄6.0(4.0,9.0)岁,男368例(84.4%)、女68例(15.6%)。
- 临床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为4例(0.9%)、30例(6.9%)、217例(49.8%)、185例(42.4%)。
- 危险度A、B1、B2、C1、C2组分别为1例(0.2%)、46例(10.6%)、19例(4.4%)、285例(65.4%)、85例(19.5%)。
- 21例(4.8%)治疗中进展,3例(0.7%)复发,13例(3.0%)治疗相关死亡。
- 随访时间24.0(13.0,35.0)个月,全组2年EFS为(90.9±1.4)%。
关键数值与推荐
- A、B1、B2、C1、C2组2年EFS分别为100.0%、100.0%、(94.7±5.1)%、(90.7±1.7)%、(85.9±4.0)%。
- A、B1、B2组整体2年EFS高于C1组(χ2=4.16,P=0.041)和C2组(χ2=7.21,P=0.007)。
- 单纯化疗组和利妥昔单抗联合化疗组2年EFS分别为(79.3±5.1)%、(92.9±1.4)%,差异有统计学意义(χ2=14.23,P<0.001)。
- 临床分期Ⅳ期(包括白血病期)、血清LDH>正常值4倍、中期评估有瘤灶为预后不良危险因素(HR=1.38、1.23、8.52,95%CI 1.05~1.82、1.05~1.43、3.96~18.30)。
临床怎么用
- 儿童伯基特淋巴瘤可按CNCL-B-NHL-2017方案进行分层治疗。
- 化疗基础上联合利妥昔单抗可提高无事件生存率。
- 临床分期Ⅳ期、LDH>正常值4倍及中期评估有瘤灶者需关注预后不良风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To analyze the clinical characteristics of children with Burkitt lymphoma (BL) and to summarize the mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 (CNCL-B-NHL-2017) regimen. Methods: Clinical features of 436 BL patients who were ≤18 years old and treated with the CNCL-B-NHL-2017 regimen from May 2017 to April 2021 were analyzed retrospectively. Clinical characteristics of patients at disease onset were analyzed and the therapeutic effects of patients with different clinical stages and risk groups were compared. Survival analysis was performed by Kaplan-Meier method, and Cox regression was used to identify the prognostic factors. Results: Among 436 patients, there were 368 (84.4%) males and 68 (15.6%) females, the age of disease onset was 6.0 (4.0, 9.0) years old. According to the St. Jude staging system, there were 4 patients (0.9%) with stage Ⅰ, 30 patients (6.9%) with stage Ⅱ, 217 patients (49.8%) with stage Ⅲ, and 185 patients (42.4%) with stage Ⅳ. All patients were stratified into following risk groups: group A (n=1, 0.2%), group B1 (n=46, 10.6%), group B2 (n=19, 4.4%), group C1 (n=285, 65.4%), group C2 (n=85, 19.5%). Sixty-three patients (14.4%) were treated with chemotherapy only and 373 patients (85.6%) were treated with chemotherapy combined with rituximab. Twenty-one patients (4.8%) suffered from progressive disease, 3 patients (0.7%) relapsed, and 13 patients (3.0%) died of treatment-related complications. The follow-up time of all patients was 24.0 (13.0, 35.0) months, the 2-year event free survival (EFS) rate of all patients was (90.9±1.4) %. The 2-year EFS rates of group A, B1, B2, C1 and C2 were 100.0%, 100.0%, (94.7±5.1) %, (90.7±1.7) % and (85.9±4.0) %, respectively. The 2-year EFS rates was higher in group A, B1, and B2 than those in group C1 (χ2=4.16, P=0.041) and group C2 (χ2=7.21, P=0.007). The 2-year EFS rates of the patients treated with chemotherapy alone and those treated with chemotherapy combined with rituximab were (79.3±5.1)% and (92.9±1.4)% (χ2=14.23, P<0.001) respectively. Multivariate analysis showed that stage Ⅳ (including leukemia stage), serum lactate dehydrogenase (LDH)>4-fold normal value, and with residual tumor in the mid-term evaluation were risk factors for poor prognosis (HR=1.38,1.23,8.52,95%CI 1.05-1.82,1.05-1.43,3.96-18.30). Conclusions: The CNCL-B-NHL-2017 regimen show significant effect in the treatment of pediatric BL. The combination of rituximab improve the efficacy further. 目的: 分析儿童伯基特淋巴瘤(BL)的临床特点,总结中国儿童淋巴瘤协作组成熟B细胞淋巴瘤2017方案(CNCL-B-NHL-2017)的中期疗效。 方法: 回顾性收集中国儿童淋巴瘤协作组2017年5月至2021年4月收治的436例年龄≤18岁BL患儿临床资料,均按照CNCL-B-NHL-2017方案分层治疗。分析患儿发病时临床特点,比较不同临床分期、危险度分组患儿的治疗效果,采用Kaplan-Meier方法进行生存分析,Cox回归分析影响预后的危险因素。 结果: 436例患儿发病年龄6.0(4.0,9.0)岁,男368例(84.4%)、女68例(15.6%)。临床分期Ⅰ、Ⅱ、Ⅲ、Ⅳ期分别为4例(0.9%)、30例(6.9%)、217例(49.8%)、185例(42.4%),危险度A、B1、B2、C1、C2组分别为1例(0.2%)、46例(10.6%)、19例(4.4%)、285例(65.4%)、85例(19.5%)。全组患儿中63例(14.4%)单纯化疗,373例(85.6%)在化疗基础上联合应用利妥昔单抗。21例(4.8%)治疗中进展,3例(0.7%)复发,13例(3.0%)治疗相关死亡。随访时间24.0(13.0,35.0)个月,全组患儿2年无事件生存率(EFS)为(90.9±1.4)%,A、B1、B2、C1、C2组2年EFS分别为100.0%、100.0%、(94.7±5.1)%、(90.7±1.7)%、(85.9±4.0)%,A、B1、B2组整体高于C1组(χ2=4.16,P=0.041)和C2组(χ2=7.21,P=0.007)。单纯化疗组和利妥昔单抗联合化疗组2年EFS分别为(79.3±5.1)%、(92.9±1.4)%,差异有统计学意义(χ2=14.23,P<0.001)。临床分期Ⅳ期(包括白血病期)、血清乳酸脱氢酶(LDH)>正常值4倍、中期评估有瘤灶为预后不良的危险因素(HR=1.38、1.23、8.52,95%CI 1.05~1.82、1.05~1.43、3.96~18.30)。 结论: CNCL-B-NHL-2017方案对儿童BL疗效显著,联合应用利妥昔单抗可以使疗效进一步提高。.
引用
- Zhang M, Wu P, Duan YL, et al. [Mid-term efficacy of China Net Childhood Lymphoma-mature B-cell lymphoma 2017 regimen in the treatment of pediatric Burkitt lymphoma]. Zhonghua Er Ke Za Zhi. 2022. PMID: 36207847. doi:10.3760/cma.j.cn112140-20220429-00390
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。